ECM | MULTIPLE MYELOMA IN THE ERA OF IMMUNOTHERAPY: A REAPPRAISAL
Multiple myeloma (MM) is a heterogeneous neoplastic disease, which is able to evade the endogenous immune response through various mechanisms. As a result, the immune system of patients with MM is extremely altered, favouring the development and growth of tumour cells.
Unlike classic drugs with direct cytotoxic action, immunotherapy relies primarily on the lysis of tumour cells induced by components of the immune system. This peculiarity allows immunotherapy to be complementary to other anti-myeloma agents and to overcome possible resistance to conventional drugs.
Several immunotherapeutic drugs such as immunomodulatory drugs, monoclonal antibodies, bispecific antibodies and CAR-T cell therapy are already part of clinical practice in MM.
The aim of the conference is to evaluate the correct use and sequencing of the therapies available today for the treatment of MM through a confrontation by a panel of international experts from Austria, Germany and Italy.
The event is addressed to an interdisciplinary medical audience not only from Haematology but also from the oncological, internistic, radiological and nephrological fields.
SCIENTIFIC BOARD
Atto Billio | Division of Hematology and BMT Unit Bolzano Hospital | IT
Dominik Wolf | Internal Medicine V: Haematology & Oncology | Innsbruck University Hospital | AT
Wolfgang Willenbacher | Internal Medicine V: Haematology & Oncology | Innsbruck University Hospital | AT
Norbert Pescosta | Division of Hematology and BMT Unit | Bolzano Hospital | IT
Scientific Congress Director | Atto Billio
CONGRESS VENUE
Conference Hall, EURAC Research Bolzano | Viale Druso, 1 | 39100 Bolzano
VIEW PROGRAM | Program
MINISTRY OF HEALTH CREDITS | VALID FOR ITALIAN CME ONLY
L’evento è accreditato ECM (Italia) e si rivolge a tutte le professioni sanitarie.
Crediti ECM: 7 | ID Evento: 2403-423551.
Obiettivo formativo: contenuti tecnico-professionali (conoscenze e competenze) specifici di ciascuna professione, di ciascuna specializzazione e di ciascuna attività ultraspecialistica, ivi incluse le malattie rare e la medicina di genere (18).
Il TEST ECM sarà fruibile da piattaforma FAD Organizing per la durata di 3 giorni dalla data di inizio dell’evento.
Il Symposium del 23 novembre è fuori campo ECM.
REGISTRATION
This event will be available exclusively in presence at the designated venue.
Congress registration is free and it allows access to in presence congress speeches.